Progyny

Progyny EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Progyny (PGNY) as of Nov 13, 2026 is 85.28 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 67.46 M USD — a change of 26.42% (higher).

EBITDA

85.28 MUSD

YoY

26.42%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Progyny is 2025 85.28 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Progyny was 2024 67.46 M USD. It decreases by 26.42% higher compared to the previous year.

The Progyny EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-6.40 M USD
Jan 1, 2019
9.68 M USD
Jan 1, 2020
8.35 M USD
Jan 1, 2021
32.34 M USD
Jan 1, 2022
23.34 M USD
Jan 1, 2023
62.18 M USD
Jan 1, 2024
67.46 M USD
Jan 1, 2025
85.28 M USD
The Progyny EBITDA history
YEAREBITDAYoY
85.28 MUSD+26.42%
67.46 MUSD+8.48%
62.18 MUSD+166.42%
23.34 MUSD-27.83%
32.34 MUSD+287.40%
8.35 MUSD-13.73%
9.68 MUSD-251.30%
-6.40 MUSD-45.42%
-11.72 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Progyny Stock analysis

What does Progyny do? Progyny Inc. is a company specializing in reproductive medicine and fertility treatments. It was founded in New York City in 2008 and has been listed on the NASDAQ stock exchange since 2019. The idea for Progyny arose when founder Gina Bartasi herself had difficulty getting pregnant and was searching for support and transparent information. She recognized the need to offer a better and more accessible service for people with fertility problems, thus founding Progyny. Progyny's business model is to offer employers a fertility benefit to help their employees, especially women, with family planning. It provides customized fertility treatments and financial assistance through its innovative programs. This allows employers to position themselves as progressive and inclusive while also increasing the bond and well-being of their employees. The different divisions of Progyny include fertility management, fertility measurement and monitoring, and fertility benefits. The fertility management solutions provide companies with comprehensive care for their employees, including counseling and support on fertility and family planning. They also provide access to an exclusive network practice specializing in reproductive medicine, including in vitro fertilization (IVF) and egg donation. The fertility measurement and monitoring program offers a personalized fertility profile that allows employees to track their fertility status to maximize their chances of a successful pregnancy. Progyny utilizes advanced methods of artificial intelligence and machine learning for this purpose. Progyny's fertility benefits include financial support for fertility treatments and medications that are not normally covered by health insurance. Additionally, the company offers a unique membership option that provides unlimited access to master fertility practices for one year. Progyny also offers a comprehensive patient experience through world-leading doctors and a patented technology platform. The platform provides support in navigating the fertility process and ensures that patients receive the best possible medical and financial care. Overall, Progyny has a significant impact on the field of reproductive medicine. With an innovative solution tailored to the needs of employers and strong support for aspiring parents, the company achieves a higher success rate in pregnancy compared to traditional fertility treatments. Progyny's technology platform improves workflow efficiency and communication in the practice, leading to a better patient experience and greater engagement. Overall, Progyny offers a holistic solution for employers and employees tailored to the unique challenges of family planning and fertility. With innovative approaches and a focus on the well-being of female employees, the company has taken a unique position in the market and is expected to continue to play a strong role in the industry. Progyny is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Progyny stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Progyny is 85.28 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Progyny changed from 67.46 M USD to 85.28 M USD, representing a 26.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Progyny since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Progyny historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Progyny

All Key Metrics — Progyny